Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isla S Mackenzie

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
European Journal of Preventive Cardiology|August 13, 2025
Ischaemic cardiovascular risk with allopurinol and protective effect of colchicine in gout: a Dutch nationwide pharmaco-epidemiological studyIris Rose Peeters, Maike H M Wientjes, Isla S Mackenzie, et al.
Journal of Pharmaceutical Sciences|May 29, 2024
Impact of Post Manufacturing Handling of Protein-Based Biologic Drugs on Product Quality and User CentricityElia Cappelletto, Stanley C Kwok, Léa Sorret, et al.
Lancet (London, England)|October 14, 2022
Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trialIsla S Mackenzie, Amy Rogers, Neil R Poulter, et al.
Pharmacoepidemiology and Drug Safety|January 4, 2020
Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The NetherlandsDaniel R Morales, Steve V Morant, Thomas M MacDonald, et al.
British Journal of Clinical Pharmacology|July 16, 2020
Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysisDaniel R Morales, Steven V Morant, Thomas M MacDonald, et al.
Health Technology Assessment (Winchester, England)|March 29, 2024
Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluationIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
Lancet (London, England)|October 10, 2022
Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trialIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
European Heart Journal|October 6, 2016
Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT)Thomas M MacDonald, Chris J Hawkey, Ian Ford, et al.
The Lancet. Primary Care|June 18, 2026
Chemical adherence testing-guided intervention versus standard of care in patients with hypertension who are non-adherent to antihypertensive treatment in the UK (OUTREACH): a multicentre, randomised controlled trialMaciej Tomaszewski, Pankaj Gupta, Philip Chowienczyk, et al.
Contemporary Clinical Trials|March 27, 2024
Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trialsMatthew R Sydes, Macey L Murray, Saiam Ahmed, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
European Journal of Preventive Cardiology|August 13, 2025
Ischaemic cardiovascular risk with allopurinol and protective effect of colchicine in gout: a Dutch nationwide pharmaco-epidemiological studyIris Rose Peeters, Maike H M Wientjes, Isla S Mackenzie, et al.
Journal of Pharmaceutical Sciences|May 29, 2024
Impact of Post Manufacturing Handling of Protein-Based Biologic Drugs on Product Quality and User CentricityElia Cappelletto, Stanley C Kwok, Léa Sorret, et al.
Lancet (London, England)|October 14, 2022
Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trialIsla S Mackenzie, Amy Rogers, Neil R Poulter, et al.
Pharmacoepidemiology and Drug Safety|January 4, 2020
Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The NetherlandsDaniel R Morales, Steve V Morant, Thomas M MacDonald, et al.
British Journal of Clinical Pharmacology|July 16, 2020
Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysisDaniel R Morales, Steven V Morant, Thomas M MacDonald, et al.
Health Technology Assessment (Winchester, England)|March 29, 2024
Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluationIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
Lancet (London, England)|October 10, 2022
Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trialIsla S Mackenzie, Christopher J Hawkey, Ian Ford, et al.
European Heart Journal|October 6, 2016
Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT)Thomas M MacDonald, Chris J Hawkey, Ian Ford, et al.
The Lancet. Primary Care|June 18, 2026
Chemical adherence testing-guided intervention versus standard of care in patients with hypertension who are non-adherent to antihypertensive treatment in the UK (OUTREACH): a multicentre, randomised controlled trialMaciej Tomaszewski, Pankaj Gupta, Philip Chowienczyk, et al.
Contemporary Clinical Trials|March 27, 2024
Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trialsMatthew R Sydes, Macey L Murray, Saiam Ahmed, et al.
Pageof 9